Our results confirmed that the expression of FOXC2 was decreased in mouse activated HSCs after tail vein injection of AAV6 FOXC2 shRNA (Fig. S7A-S7B), which were consistent with previous results27, 28.Furthermore, the Sirius Red staining, masson staining and hydroxyproline analysis exhibited that CCl4 injection or BDL induced mice liver fibrosis, while the degree of fibrogenesis was alleviated upon AAV6-shFOXC2 treatment (Fig. 8A-8B, Fig.8D-8E, Fig.S8A-S8C and Fig.S9B). The gene discussed is FOXC2; the disease is Hepatic fibrosis.